13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q1 2016. See the latest, Q3 2026 →

Reported value

$6.92B

First quarter on file

Positions

36

First quarter on file

Top 10

79.9%

of the value

Est. gain

—

Nothing to compare

Est. return

—

Nothing to compare

Filed

May 13, 2016

On SEC EDGAR ↗

Positions as of Mar 31, 2016, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

Each tile is a position, sized by its share. Striped tiles are options.

E M C Corp Mass20%
Cheniere Energy Inc15%
Viasat Inc12%
Antero Res Corp7.7%
Allergan Plc6.7%
Pbf Energy Inc5.1%
PayPal3.9%
Innoviva Inc3.6%
Twenty First Centy Fox Inc3.1%
Twenty First Centy Fox Inc3.0%
Olin Corp2.7%
12 others2.4%
Theravance Biopharma Inc1.8%
Keryx Biopharmaceuticals Inc1.7%
Vmware Inc1.7%
Veritiv Corp1.6%
Atara Biotherapeutics Inc1.5%
Forward Pharma A/S1.3%
Novagold Res Inc1.1%
Chipmos Tech Bermuda Ltd0.9%
Klx Inc0.9%
0.8%
0.6%
0.6%
0.5%

Holdings

As of Mar 31, 2016, the first quarter on file.

Positions, sorted by share of the portfolio
HoldingValue
E M C Corp MassCOM20.0%$1.38B
Cheniere Energy IncCOM NEW14.6%$1.01B
Viasat IncCOM12.2%$847.5M
Antero Res CorpCOM7.7%$534.9M
Allergan PlcSHS6.7%$461.4M
Pbf Energy IncCL A5.1%$353.3M
PayPalCOM3.9%$272.5M
Innoviva IncCOM3.6%$249.5M
Twenty First Centy Fox IncCL A3.1%$214.6M
Twenty First Centy Fox IncCL B3.0%$205.2M
Olin CorpCOM PAR $12.7%$186.5M
Theravance Biopharma IncCOM1.8%$122.2M
Keryx Biopharmaceuticals IncCOM1.7%$120.4M
Vmware IncCL A COM1.7%$117.8M
Veritiv CorpCOM1.6%$113.4M
Atara Biotherapeutics IncCOM1.5%$102.0M
Forward Pharma A/SSPONSORED ADR1.3%$91.2M
Novagold Res IncCOM NEW1.1%$75.6M
Chipmos Tech Bermuda LtdSHS0.94%$65.2M
Klx IncCOM0.93%$64.3M
Sunedison Semiconductor LtdSHS0.78%$54.3M
American Intl Group Inc*W EXP 01/19/2020.57%$39.7M
Silver Run Acquisition CorpUNIT 99/99/9999T0.56%$38.8M
Theravance IncNOTE 2.125% 1/10.55%$37.8M
Biotie Therapies OyjSPONSORED ADR0.53%$36.8M
Total 36 positions100%$6.92B

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free